ALKEM2021-04-012021-06-30in-bse-fin:OneOperatingExpenses01Member ALKEM2021-04-012021-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares ALKEM 2021-04-01 2022-03-31 2021-07-26 INR Millions First quarter Single segment The Company is exclusively engaged in pharmaceutical business 2021-04-01 2021-06-30 Unaudited Standalone 22786700000.00 392100000.00 23178800000.00 6538100000.00 2629700000.00 -41600000.00 4022300000.00 90600000.00 517200000.00 4132500000.00 17888800000.00 5290000000.00 0.00 5290000000.00 916200000.00 -318900000.00 597300000.00 0.00 4692700000.00 0.00 0.00 0.00 0.00 4692700000.00 -10400000.00 4682300000.00 0.00 0.00 239100000.00 2 39.25 39.25 0.00 0.00 39.25 39.25 1. The above unaudited standalone financial results of the Company were reviewed and recommended by the Audit Committee on 5 August 2021 and subsequently approved by the Board of Directors at its meeting held on 6 August 2021. The auditors have issued an unmodified report on the financial results for the quarter ended 30 June 2021. The figures for the quarter ended 31 March 2021 are balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter ended 31 December 2020, which were subjected to limited review. 2. The Company has considered internal and external information while assessing recoverability of its assets upto the date of approval of these financial results by the Board of Directors. Based on such assessment and considering the current economic indicators, the Company expects to recover the carrying amount of these assets. The Board of Directors has also considered the impact of COVID-19 on the business for the foreseeable future and have concluded that the Company has sufficient resources to continue as a going concern. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the Company will continue to closely monitor any material changes to future economic conditions. 3. The Company has made an assessment of the recoverable value of investment in its subsidiaries taking into account the decline in operational performance, changes in the outlook of future profitability, weaker market conditions, among other potential indicators. Accordingly, during the quarter ended 31 March 2021, an impairment loss of Rs.127.8 Million has been recognised towards investment in Alkem Laboratories Corporation, Philippines, a wholly owned subsidiary of the Company in accordance with IND AS 36 ‘Impairment of assets’ and the same has been disclosed as an 'Exceptional item'. 4. The Company operates in one reportable business segment i.e. Pharmaceuticals , accordingly no separate disclosure of segment has been made. 5. Previous period figures have been regrouped/reclassified wherever required, to make them comparable with the figures for the current period. Other expenses 4132500000.00